StreetInsider.com News Articles

D. Boral Capital Downgrades Reviva Pharmaceuticals (RVPH) to Hold

Thu, 05 Mar 2026 08:46:26 -0500

D. Boral Capital analyst Jason Kolbert downgraded Reviva Pharmaceuticals (NASDAQ: RVPH) from Buy to Hold.

The analyst comments "Reviva Pharmaceuticals announced a 1-for-20 reverse stock split through an 8-K filing, prompting us to lower our rating from Buy to Hold. While the reverse split does not change the company’s underlying fundamentals or shareholder ownership percentages, such actions are typically associated with weak share price performance and attempts to maintain exchange listing compliance. Historically, reverse splits tend to be followed by continued pressure on the stock, as the structural issues that drove the share price decline often remain unresolved."

For an analyst ratings

D. Boral Capital Downgrades Reviva Pharmaceuticals (RVPH) to Hold

Thu, 05 Mar 2026 08:46:26 -0500

D. Boral Capital analyst Jason Kolbert downgraded Reviva Pharmaceuticals (NASDAQ: RVPH) from Buy to Hold.

For an analyst ratings

Form 8-K REVIVA PHARMACEUTICALS For: Mar 04

Thu, 05 Mar 2026 08:01:00 -0500

si-local-file:///var/storage/secattach/20260305/26115448.html

Form 8-K REVIVA PHARMACEUTICALS For: Mar 04

Thu, 05 Mar 2026 08:01:00 -0500

si-local-file:///var/storage/secattach/20260305/26115448.html

Form SCHEDULE 13G/A REVIVA PHARMACEUTICALS Filed by: 683 Capital Management, LLC

Tue, 17 Feb 2026 16:20:00 -0500

si-local-file:///var/storage/secattach/20260217/26013349.html

Form SCHEDULE 13G/A REVIVA PHARMACEUTICALS Filed by: 683 Capital Management, LLC

Tue, 17 Feb 2026 16:20:00 -0500

si-local-file:///var/storage/secattach/20260217/26013349.html

Form 8-K REVIVA PHARMACEUTICALS For: Jan 20

Fri, 23 Jan 2026 16:15:00 -0500

si-local-file:///var/storage/secattach/20260123/25887273.html

Form 8-K REVIVA PHARMACEUTICALS For: Jan 20

Fri, 23 Jan 2026 16:15:00 -0500

si-local-file:///var/storage/secattach/20260123/25887273.html

Form SCHEDULE 13G/A REVIVA PHARMACEUTICALS Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Fri, 16 Jan 2026 16:52:00 -0500

si-local-file:///var/storage/secattach/20260116/25860964.html

Form SCHEDULE 13G/A REVIVA PHARMACEUTICALS Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Fri, 16 Jan 2026 16:52:00 -0500

si-local-file:///var/storage/secattach/20260116/25860964.html

Reviva publishes vocal biomarker data from brilaroxazine Phase 3 trial

Thu, 08 Jan 2026 08:03:04 -0500

Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) announced the publication of vocal biomarker data from its RECOVER Phase 3 clinical trial of brilaroxazine for treating negative symptoms in schizophrenia. The article appeared in the peer-reviewed journal Biological Psychiatry.

The publication examines speech latency as a biomarker tool for clinical trials. According to the study, speech latencies classified patients with moderate to severe negative symptoms versus those with low negative symptoms in the RECOVER trial. A greater percentage of patients with positive vocal biomarker results showed significant treatment response to brilaroxazine across multiple symptom domains of schizophrenia.

The research found that patients with positive

Reviva publishes vocal biomarker data from brilaroxazine Phase 3 trial

Thu, 08 Jan 2026 08:03:04 -0500

The research found that patients with positive

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

Thu, 08 Jan 2026 08:00:00 -0500

Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in a Phase 3 trial of brilaroxazine

Findings also support use of speech latency as an enrichment tool that can reduce sample-size and enhance outcomes in clinical trials for schizophrenia

CUPERTINO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases,

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

Thu, 08 Jan 2026 08:00:00 -0500

Findings also support use of speech latency as an enrichment tool that can reduce sample-size and enhance outcomes in clinical trials for schizophrenia

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

Thu, 08 Jan 2026 08:00:00 -0500

Findings also support use of speech latency as an enrichment tool that can reduce sample-size and enhance outcomes in clinical trials for schizophrenia

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

Thu, 08 Jan 2026 08:00:00 -0500

Findings also support use of speech latency as an enrichment tool that can reduce sample-size and enhance outcomes in clinical trials for schizophrenia

Chardan Capital Markets Assumes Reviva Pharmaceuticals (RVPH) at Buy

Mon, 05 Jan 2026 04:35:25 -0500

(Updated - January 5, 2026 4:35 AM EST)

Chardan Capital Markets analyst Keay Nakae assumes coverage on Reviva Pharmaceuticals (NASDAQ: RVPH) with a Buy rating and a price target of $2.00.

The analyst comments "We are transferring coverage of Reviva Pharmaceuticals (RVPH) to Keay Nakae, CFA. We maintain our Buy rating and set our price target at $2 based on the potential of its lead asset brilaroxazine as a next-gen antipsychotic product. We believe that brilaroxazine has demonstrated robust treatment benefits for the lead indication, schizophrenia, across phase I/II/III studies and the safety profile has been favorable. Reviva's brilaroxazine is a novel,

Chardan Capital Markets Assumes Reviva Pharmaceuticals (RVPH) at Buy

Mon, 05 Jan 2026 04:35:25 -0500

(Updated - January 5, 2026 4:35 AM EST)

Chardan Capital Markets analyst Keay Nakae assumes coverage on Reviva Pharmaceuticals (NASDAQ: RVPH) with a Buy rating and a price target of $2.00.

Chardan Capital Markets Assumes Reviva Pharmaceuticals (RVPH) at Buy

Mon, 05 Jan 2026 04:35:25 -0500

(Updated - January 5, 2026 4:35 AM EST)

Chardan Capital Markets analyst Keay Nakae assumes coverage on Reviva Pharmaceuticals (NASDAQ: RVPH) with a Buy rating and a price target of $2.00.

Chardan Capital Markets Assumes Reviva Pharmaceuticals (RVPH) at Buy

Mon, 05 Jan 2026 04:35:25 -0500

(Updated - January 5, 2026 4:35 AM EST)

Chardan Capital Markets analyst Keay Nakae assumes coverage on Reviva Pharmaceuticals (NASDAQ: RVPH) with a Buy rating and a price target of $2.00.

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

Mon, 29 Dec 2025 08:00:00 -0500

CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Sachs 9th Annual Neuroscience Innovation Forum, taking place January 11, 2026, in San Francisco, CA.

Presentation Details:

Format: Corporate Presentation
Date: Sunday, January 11, 2026
Time: 1:20 PM PT
Presenter: Laxminarayan Bhat, Ph.D., Reviva Pharmaceuticals
Location: Marines’ Memorial

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

Mon, 29 Dec 2025 08:00:00 -0500

Presentation Details:

Format: Corporate Presentation
Date: Sunday, January 11, 2026
Time: 1:20 PM PT
Presenter: Laxminarayan Bhat, Ph.D., Reviva Pharmaceuticals
Location: Marines’ Memorial

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

Mon, 29 Dec 2025 08:00:00 -0500

Presentation Details:

Format: Corporate Presentation
Date: Sunday, January 11, 2026
Time: 1:20 PM PT
Presenter: Laxminarayan Bhat, Ph.D., Reviva Pharmaceuticals
Location: Marines’ Memorial

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

Mon, 29 Dec 2025 08:00:00 -0500

Presentation Details:

Format: Corporate Presentation
Date: Sunday, January 11, 2026
Time: 1:20 PM PT
Presenter: Laxminarayan Bhat, Ph.D., Reviva Pharmaceuticals
Location: Marines’ Memorial

H.C. Wainwright Reiterates Buy Rating on Reviva Pharmaceuticals (RVPH)

Wed, 24 Dec 2025 06:44:42 -0500

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $4.00 price target on Reviva Pharmaceuticals (NASDAQ: RVPH).

The analyst commented: "In written feedback, the FDA recommended a second Phase 3 clinical trial for brilaroxazine in patients with schizophrenia to, among other things, generate additional efficacy data and expand the safety dataset pursuant to the submission of a New Drug Application (NDA). Subject to sufficient financing, Reviva plans to initiate the RECOVER-2 Phase 3 trial in 1H26. The RECOVER-2 trial will be similar in design to the completed RECOVER Phase 3 trial of brilaroxazine. The FDA also provided the company with